{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:54:01Z","timestamp":1793084041017,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-024-03470-y","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T06:22:57Z","timestamp":1736922177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis"],"prefix":"10.1186","volume":"27","author":[{"given":"Alberto","family":"Floris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Angioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela Rita","family":"Naitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Chessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"3470_CR1","doi-asserted-by":"crossref","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"3470_CR2","doi-asserted-by":"crossref","unstructured":"Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, van Laar JM, Lafeber FPJG, et al. Is prediction of clinical response to methotrexate in individual rheumatoid arthritis patients possible? A systematic literature review. Joint Bone Spine. 2020;87:13\u201323.","DOI":"10.1016\/j.jbspin.2019.04.002"},{"key":"3470_CR3","doi-asserted-by":"crossref","unstructured":"Narv\u00e1ez J, Magallares B, D\u00edaz Torn\u00e9 C, Hern\u00e1ndez MV, Reina D, Corominas H, et al. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum. 2016;45:386\u201390.","DOI":"10.1016\/j.semarthrit.2015.07.001"},{"key":"3470_CR4","doi-asserted-by":"crossref","unstructured":"Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5:185\u20136.","DOI":"10.1038\/nrd1989"},{"key":"3470_CR5","doi-asserted-by":"crossref","unstructured":"Blair HA, Deeks ED. Abatacept: A Review in Rheumatoid Arthritis. Drugs. 2017;77:1221\u201333.","DOI":"10.1007\/s40265-017-0775-4"},{"key":"3470_CR6","doi-asserted-by":"crossref","unstructured":"Alten R, Mariette X, Lorenz H-M, Galeazzi M, Cantagrel A, N\u00fc\u00dflein HG, et al. Real-world predictors of 12\u2013month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open. 2017;3:e000538.","DOI":"10.1136\/rmdopen-2017-000538"},{"key":"3470_CR7","doi-asserted-by":"crossref","unstructured":"Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016;75:709\u201314.","DOI":"10.1136\/annrheumdis-2015-207942"},{"key":"3470_CR8","doi-asserted-by":"crossref","unstructured":"Ajeganova S, Huizinga TWJ. Seronegative and seropositive RA: alike but different? Nat Rev Rheumatol. 2015;11:8\u20139.","DOI":"10.1038\/nrrheum.2014.194"},{"key":"3470_CR9","doi-asserted-by":"crossref","unstructured":"Kolarz B, Ciesla M, Rosenthal AK, Dryglewska M, Majdan M. The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA\/RF negative rheumatoid arthritis patients. Ther Adv Musculoskelet Dis. 2021;13:1759720\u2009\u00d7\u200921,989,868.","DOI":"10.1177\/1759720X21989868"},{"key":"3470_CR10","doi-asserted-by":"crossref","unstructured":"Boeters DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW. Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. Arthritis Res Ther. 2018;20:94.","DOI":"10.1186\/s13075-018-1591-2"},{"key":"3470_CR11","doi-asserted-by":"crossref","unstructured":"Pollmann S, Stensland M, Halvorsen EH, Sollid LM, Kvien TK, Fleckenstein B, et al. Anti-PAD4 autoantibodies in rheumatoid arthritis: levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate. Rheumatol Int. 2012;32:1271\u20136.","DOI":"10.1007\/s00296-010-1765-y"},{"key":"3470_CR12","unstructured":"Yang X, Wang M, Zhang X, Li X, Cai G, Xia Q, et al. Diagnostic accuracy of anti-RA33 antibody for rheumatoid arthritis: systematic review and meta-analysis. Clin Exp Rheumatol. 2016;34:539\u201347."},{"key":"3470_CR13","doi-asserted-by":"crossref","unstructured":"Martinez-Prat L, Lucia D, Ibarra C, Mahler M, Dervieux T. Antibodies targeting protein-arginine deiminase 4 (PAD4) demonstrate diagnostic value in rheumatoid arthritis. Ann Rheum Dis. 2019;78:434\u20136.","DOI":"10.1136\/annrheumdis-2018-213818"},{"key":"3470_CR14","doi-asserted-by":"publisher","unstructured":"Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A. Erosive Rheumatoid Arthritis Is Associated with Antibodies That Activate PAD4 by Increasing Calcium Sensitivity. Sci Transl Med. 2013 [cited 2024 Jul 15];5. Available from: https:\/\/www.science.orghttps:\/\/doi.org\/10.1126\/scitranslmed.3005370.","DOI":"10.1126\/scitranslmed.3005370"},{"key":"3470_CR15","doi-asserted-by":"crossref","unstructured":"Shi J, Stadt LA van de, Levarht EWN, Huizinga TWJ, Hamann D, Schaardenburg D van, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780\u20133.","DOI":"10.1136\/annrheumdis-2013-204154"},{"key":"3470_CR16","doi-asserted-by":"crossref","unstructured":"van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020;102,392.","DOI":"10.1016\/j.jaut.2019.102392"},{"key":"3470_CR17","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","DOI":"10.1002\/art.27584"},{"key":"3470_CR18","unstructured":"van Riel PLCM, Renskers L. The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:S40\u20134."},{"key":"3470_CR19","doi-asserted-by":"crossref","unstructured":"Halvorsen EH, Pollmann S, Gilboe I-M, Heijde D van der, Landew\u00e9 R, \u00d8deg\u00e5rd S, et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis. 2008;67:414\u20137.","DOI":"10.1136\/ard.2007.080267"},{"key":"3470_CR20","doi-asserted-by":"crossref","unstructured":"Martinez-Prat L, Martinez-Taboada V, Santos C, Lopez-Hoyos M, Mahler M. Anti-Protein-Arginine Deiminase 4 IgG and IgA Delineate Severe Rheumatoid Arthritis. Diagn Basel Switz. 2022;12:2187.","DOI":"10.3390\/diagnostics12092187"},{"key":"3470_CR21","doi-asserted-by":"crossref","unstructured":"Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the \u2018Orencia and Rheumatoid Arthritis\u2019 registry. Ann Rheum Dis. 2012;71:1815\u20139.","DOI":"10.1136\/annrheumdis-2011-201109"},{"key":"3470_CR22","doi-asserted-by":"crossref","unstructured":"Manfredi A, Fornaro M, Bazzani C, Perniola S, Cauli A, Rai A, et al. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry. Front Med. 2024 [cited 2024 May 24];11. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1349533.","DOI":"10.3389\/fmed.2024.1349533"},{"key":"3470_CR23","doi-asserted-by":"crossref","unstructured":"Zhang G, Xu J, Du D, Liu Y, Dai L, Zhao Y. Diagnostic values, association with disease activity and possible risk factors of anti-PAD4 in rheumatoid arthritis: a meta-analysis. Rheumatology. 2024;63:914\u201324.","DOI":"10.1093\/rheumatology\/kead545"},{"key":"3470_CR24","doi-asserted-by":"crossref","unstructured":"Kumar R, Piantoni S, Boldini M, Garrafa E, Bazzani C, Fredi M, et al. Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. Clin Exp Rheumatol. 2021;39:91\u20137.","DOI":"10.55563\/clinexprheumatol\/g8xqxr"},{"key":"3470_CR25","doi-asserted-by":"crossref","unstructured":"Castellanos-Moreira R, Rodr\u00edguez-Garc\u00eda SC, Gomara MJ, Ruiz-Esquide V, Cuervo A, Casafont-Sol\u00e9 I, et al. Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis. 2020;79:587\u201394.","DOI":"10.1136\/annrheumdis-2019-216709"},{"key":"3470_CR26","doi-asserted-by":"crossref","unstructured":"Kawashiri SY, Endo Y, Nishino A, Shimizu T, Ueki Y, Eiraku N, et al. Fri0098 Association Between the Serologic Status of Isotype-Specific Autoantibodies and Therapeutic Efficacy in Rheumatoid Arthritis Patients Treated with Abatacept: A Prospective Ultrasound Cohort Study in Japan. Ann Rheum Dis. 2020;79:628\u2013628.","DOI":"10.1136\/annrheumdis-2020-eular.2269"},{"key":"3470_CR27","doi-asserted-by":"crossref","unstructured":"Cappelli LC, Hines D, Wang H, Bingham CO, Darrah E. Anti-Peptidylarginine Deiminase 4 Autoantibodies and Disease Duration as Predictors of Treatment Response in Rheumatoid Arthritis. ACR Open Rheumatol. 2024;6:81\u201390.","DOI":"10.1002\/acr2.11630"},{"key":"3470_CR28","doi-asserted-by":"crossref","unstructured":"Pratt AG, Isaacs JD. Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. Best Pract Res Clin Rheumatol. 2014;28:651\u20139.","DOI":"10.1016\/j.berh.2014.10.016"},{"key":"3470_CR29","doi-asserted-by":"crossref","unstructured":"Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. The Lancet. 2024;403:838\u201349.","DOI":"10.1016\/S0140-6736(23)02649-1"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03470-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T06:23:10Z","timestamp":1736922190000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03470-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3470"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03470-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Local Ethical Committee (PROT. PG\/2021\/19418) of the Azienda Ospedaliero Universitaria of Cagliari and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"written informed consent for publication was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.F.: consulting and\/or speaking fees from Amgen, Eli Lilly, Janssen, Abbvie. M.C.: consulting and\/or speaking fees from Amgen, Eli Lilly, Novartis. A.C.: consulting and\/or speaking fees from Abbvie, Amgen, Biogen, BMS, Galapagos, Eli Lilly, Janssen, Novartis, Pfizer, UCB. The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}